In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.

MLA

Jiménez-Vacas, Juan M., et al. “In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.” Journal of Clinical Endocrinology & Metabolism, vol. 106, no. 12, Dec. 2021, pp. e4956–68. EBSCOhost, https://doi.org/10.1210/clinem/dgab516.

APA

Jiménez-Vacas, J. M., Montero-Hidalgo, A. J., Gómez-Gómez, E., Fuentes-Fayos, A. C., Ruiz-Pino, F., Guler, I., Camargo, A., Anglada, F. J., Carrasco-Valiente, J., Tena-Sempere, M., Sarmento-Cabral, A., Castaño, J. P., Gahete, M. D., & Luque, R. M. (2021). In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer. Journal of Clinical Endocrinology & Metabolism, 106(12), e4956–e4968. https://doi.org/10.1210/clinem/dgab516

Chicago

Jiménez-Vacas, Juan M., Antonio J. Montero-Hidalgo, Enrique Gómez-Gómez, Antonio C. Fuentes-Fayos, Francisco Ruiz-Pino, Ipek Guler, Antonio Camargo, et al. 2021. “In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.” Journal of Clinical Endocrinology & Metabolism 106 (12): e4956–68. doi:10.1210/clinem/dgab516.